Holding(s) in Company

Summary by AI BETAClose X

On September 1, 2025, David John Smith's voting rights attached to shares of Hemogenyx Pharmaceuticals PLC reached 3.0376%, representing 143,594 voting rights. Subsequently, on September 4, 2025, Smith's voting rights increased to 4.7614%, totaling 240,162 voting rights, of which 3.3708% (170,021) were direct and 1.3906% (70,141) were indirect. Then, on September 8, 2025, Smith's voting rights further increased to 5.1632%, equivalent to 260,426 voting rights, with 3.7726% (190,285) held directly and 1.3906% (70,141) held indirectly. These notifications, related to the acquisition or disposal of voting rights, were issued on September 18, 2025.

Disclaimer*

UK 100

Latest directors dealings